We are pleased today to announce the appointment of James Chung, M.D., Ph.D., as the Company’s first Chief Medical Officer. Dr. Chung joins Kyverna from Amgen 🧪🔬🧬 where he most recently was Executive Medical Director. For more: kyvernatx.com/press-releases… #CMO #tamingautoimmunity

We are extremely excited to announce the appointment of Ian Clark as chair of the company's board of directors and the appointment of Karen Walker as Chief Technology Officer (CTO). Follow the link to read the full release: prnewswire.com/news-releases/…

Kyverna Therapeutics is pleased to announce we've entered into exclusive, worldwide licenses with NIH for intellectual property related to a novel clinical-stage anti-CD19 CAR T-cell construct with properties uniquely suited for use in autoimmune diseases. kyvernatx.com/press-releases…

Be sure to read BioSpace's article for more information about Kyverna Therapeutics and our recent exclusive rights licensing deal to the IP of a novel clinical-stage anti-CD19 chimeric antigen receptor T-cell with NIH. Find the full article here: biospace.com/article/kyvern… #TCELL #NIH

Kyverna Therapeutics is pleased to announce a licensing and collaboration agreement with @intelliatweets for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases. Read full release here: globenewswire.com/news-release/2…

Be sure to read BioSpace's article on Kyverna Therapeutics's exclusive agreement to develop and later commercialize an allogeneic CD19 CAR-T cell therapy to treat a wide range of B cell-mediated autoimmune illnesses with @intelliatweets. Find the article here: biospace.com/article/intell…

Kyverna Therapeutics would like to congratulate our board member and WestlakeVillageBioPartners’s co-founding managing director Dr. Beth Seidenberg on winning HBA’s Woman of the Year honor for 2022. westlakebio.com/westlakes-beth… #HBAimpact #genderequality #healthcare #HBAWOTY22

Kyverna Therapeutics is pleased to announce the successful closing of $85 million in our series B round of financing. You can read the full press release here: kyvernatx.com/press-releases… #biotech #venturecapital #investors #cartcells

Today is #WorldLupusDay - Be sure to read the article below from BioSpace to learn more about how Kyverna Therapeutics is committed to improving treatment options for patients living with lupus by utilizing an anti-CD19 CAR-T cell therapy biospace.com/article/biopha… #lupus #LupusAwareness